Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Caris Life Sciences (CAI) has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek. This ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...

Key Takeaways MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies ...

Negedia has acquired MGI's DNBSEQ-T7 high-throughput sequencing platform, which enables high-resolution spatial transcriptomic analysis, allowing for the acquisition of the entire transcriptome-i ...

Caris Life Sciences demonstrates scientific rigor with clinical validation of US FDA approved MI Cancer Seek: Irving, Texas Monday, August 18, 2025, 16:00 Hrs [IST] Caris Life Sci ...